Connect your AI

Ginkgo Bioworks DNA Change in Other Liabilities

Change in Other Liabilities at other companies

RegenxbioRGNX

-$16K+99.5%

Maravai LifeSciences Holdings, Inc.MRVI

-$203K+97.6%

CRISPR TherapeuticsCRSP

-$199K+98.1%

Other financials

Income statement

Revenue$19.5M-49.1%

Gross profit$16.4M-52.0%

Operating income-$71.4M+11.9%

Net income-$82.6M+9.2%

EPS (diluted)-$1.42+27.6%

Balance sheet

Cash & equivalents$188.7M-46.9%

Total debt$410.7M-5.5%

Total equity$443.2M-31.6%

Total assets$1.0B-20.1%

Cash flow

Operating cash flow-$46.7M+9.4%

CapEx$1.9M-74.6%

Free cash flow-$48.6M+17.8%

Valuation

Market cap$625.16M+24.6%

Enterprise value$847.19M+45.9%

P/S4.4×+2.2×

Profitability

Operating margin-210.7%+7.6pp

Net margin-215.4%+8.3pp

FCF margin-119%-21.2pp

Returns & leverage

Return on equity-55.8%-1.8pp

Debt / equity0.9×+0.3×

Current ratio5.2×+0.3×

Where this comes from

Reported directly by Ginkgo Bioworks in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities.

The official record: Ginkgo Bioworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ginkgo Bioworks's change in other liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Ginkgo Bioworks's change in other liabilities?: Ginkgo Bioworks (DNA) reported change in other liabilities of -$758K in Q1 2026.
What does change in other liabilities mean?: Change in miscellaneous liabilities affecting operating cash flow.